接棒京東!中國最大的腫瘤醫療服務集團海吉亞醫療16日開始招股
uSMART友信智投6月9日消息,據港媒經濟通和明報消息,中國最大的腫瘤醫療服務集團海吉亞醫療,將於下週二(16日)開始公開招股,19日結束,29日掛牌,集資3億美元(約23.4億元),保薦人為摩根士丹利及海通國際。
京東將於下週三(17日)公佈中簽結果,釋放的資金可以完美接棒海吉亞醫療的認購。
海吉亞醫療是一家中美合資專業化的醫療投資集團,專注於連鎖腫瘤治療及腦科醫療機構的投資、建設及運營管理。目前經營或管理10家以腫瘤科為核心的醫院,是中國最大的腫瘤醫療機構。
海吉亞的子公司伽瑪星醫療,是中國最主要的伽馬刀生產商,其聯合創始人宋世鵬被譽為“中國伽瑪刀之父”。現在海吉亞擁有42台海內最先進的專利立體定向放療設備,在專利技術方面海吉亞醫療團體處於領先職位。
海吉亞醫療獲得華平投資、中信資本(管理資產超過250億美元)、藥明康得等的投資。
其中華平於2015年投資海吉亞,持股比例高達17.48%。
華平是中國和東南亞投資規模最大、最活躍的國際私募股權投資機構之一,投資過的專案有錦欣生殖、中通快遞、ESR、螞蟻金服、印尼最大獨角獸Gojek等。
免責聲明:本文所載的所有資料、資料等(「資料」)只供參考之用,不構銷售或建議任何投資、交易策略或金融產品的要約或招攬。本公司會盡力確保資料的準確性及可靠性, 但不保證該資料為準確無誤, 亦不承擔因任何不準確或遺漏而引起的損失或損害。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.